Abstract
A relationship between response to lithium prophylaxis and T-50C polymorphism of glycogen synthase kinase-3beta (GSK-3beta) gene was investigated in 89 bipolar patients (41 male and 48 female) who have been taking lithium for at least 5 years. The patients were delineated as excellent responders, partial responders and non-responders to lithium. The results obtained suggest that this polymorphism may not be related to the degree of prophylactic lithium response.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Alleles
-
Antimanic Agents / therapeutic use*
-
Bipolar Disorder / drug therapy*
-
Bipolar Disorder / genetics*
-
Female
-
Gene Frequency / genetics
-
Genotype
-
Glycogen Synthase Kinase 3 / genetics*
-
Glycogen Synthase Kinase 3 beta
-
Homozygote
-
Humans
-
Lithium Carbonate / therapeutic use*
-
Male
-
Middle Aged
-
Polymorphism, Genetic / genetics*
-
Secondary Prevention
-
Statistics as Topic
-
Treatment Outcome
Substances
-
Antimanic Agents
-
Lithium Carbonate
-
GSK3B protein, human
-
Glycogen Synthase Kinase 3 beta
-
Glycogen Synthase Kinase 3